Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans.
Health and Human Services Department, National Institutes of Health
What is this?
This is a regulatory record from Health and Human Services Department, National Institutes of Health — a rule, proposed rule, or notice. Regulations carry the force of law once final, and often invite public comment before that point.
Why does it matter?
Regulations are usually what actually binds you, more than statutes are. This is where an agency states the requirement, the effective date, and whether there is still a window to respond.
Key Details
- Posted Date
- Response Deadline
- NAICS Code
- 541715
- Source
- Federal Register
- Contract Type
- regulation
Description
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507, entitled "Cannabinoids as antioxidants and neuroprotectants" and PCT Application Serial No. PCT/US99/08769 and foreign equivalents thereof, entitled "Cannabinoids as antioxidants and neuroprotectants" [HHS Ref. No. E-287-1997/2] to KannaLife Sciences Inc., which has offices in New York, U.S. This patent and its foreign counterparts have been assigned to the Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to:
Key Dates
Frequently Asked Questions
Does this regulation apply to me?+
Follow This Regulation
Follow this regulation in Bureauify to see changes as they are published.
Intelligence
- Win probability analysis
- Competitive landscape
- Incumbent analysis
- Price-to-win estimate
- Similar awards history